



First Quarter 2018

Earnings Call


May 10, 2018

# Forward-Looking Statements

All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such statements include possible activity, benefits and attributes of PEGPH20, future product development and regulatory events and goals, anticipated clinical trial results and strategies, product collaborations, our business intentions and financial estimates and results, including projected revenue amounts. These statements are based upon management's current plans and expectations and are subject to a number of risks and uncertainties which could cause actual results to differ materially from such statements. A discussion of the risks and uncertainties that can affect these statements is set forth in the Company's annual and quarterly reports filed from time to time with the Securities and Exchange Commission under the heading "Risk Factors." The Company disclaims any intention or obligation to revise or update any forward-looking statements, whether as a result of new information, future events, or otherwise.

# ENHANZE®: ~\$1 Billion Royalty Revenue Potential in 2027

Based on marketed products and targets projected to be in clinical testing in 2018



## Approved Products

**RituxanHYCELA™**  
rituximab/hyaluronidase human  
subcutaneous injection 1,450 mg/23,450 units  
1,600 mg/26,800 units

**Herceptin® SC**  
trastuzumab  
subcutaneous

**MabThera® SC**  
Rituximab Subcutaneous  
FAST • EASY • EFFECTIVE

**HyQvia**  
Human Normal Immunoglobulin (10%)  
Recombinant Human Hyaluronidase

## Potential Future Products<sup>1,2</sup>

Assumes additional products, including Darzalex® and Opdivo® (nivolumab), are globally approved and launched in multiple indications




<sup>1</sup> Includes projections for subcutaneous versions of targets not approved or commercially available. Innovator revenues based on Bloomberg analyst projections. Conversion rates based on Halozyyme internal projections.

<sup>2</sup> Royalty revenue projection includes targets selected but not yet disclosed.

# ENHANZE<sup>®</sup> Progress and Value Acceleration in 2018


**2017**

6 Products




**2018**

11 products



- Approved and Commercialized
- Phase 1
- Phase 3

# HALO-301 | Pancreatic: Global Phase 3 Trial Enrolling in 22 Countries



- Randomized (2:1 PAG:AG), double-blind, placebo-controlled, global
- Project to achieve target number of PFS events between December 2018 and February 2019, triggering final data collection, cleaning and interim analysis

# Robust Pan-Tumor Testing of PEGPH20

Combination	Tumor		
<b>Chemotherapy</b>			
<b>Eribulin (Halaven®)</b> <i>Eisai led</i>	<b>Breast Cancer</b>	Phase 1b Dose Finding Enrollment Closed	Data Update in 2018 <sup>1,2</sup>
<b>Checkpoint Inhibitors</b>			
<b>Pembrolizumab (Keytruda®)</b>	<b>Gastric Cancer, NSCLC</b>	Phase 1b Dose Expansion Started Jan 2017	Data Update in 2018 <sup>2</sup>
<b>Atezolizumab (Tecentriq®)</b> <i>Roche</i>	<b>Pancreas Cancer, Gastric Cancer</b>	Phase 1b Dose Finding Started 2H 2017	
<b>Atezolizumab (Tecentriq)</b>	<b>Gall Bladder Cancer, Cholangiocarcinoma</b>	Phase 1b Dose Finding Started 2H 2017	

# First Quarter 2018 Financial Highlights<sup>1</sup>

\$ U.S. in Millions (unaudited)

	1Q 2018	1Q 2017	% Change
Total Revenue	\$30.9	\$29.6	4%
Royalty Revenue	\$20.9	\$14.0	50%
Bulk rHuPH20 Sales	\$3.4	\$8.2	(59%)
Hyalenex <sup>®</sup> Recombinant	\$3.4	\$3.2	7%
Collaboration Revenue	\$3.1	\$4.2	(25%)

1) Dollar amounts and percentages, as presented, are rounded.

# First Quarter 2018 Royalty Revenue<sup>1</sup>

\$ U.S. in Millions (unaudited)

Compared to Q1 2017 (as Reported)	1Q 2018 (Estimate)	1Q 2017 (Actual)	% Change
Royalty Revenue	\$20.9	\$14.0	50%

\$ U.S. in Millions (unaudited)

Compared to Q2 2017 (Royalties Based on Q1 Partner Sales)	1Q 2018 (Estimate)	2Q 2017 (Actual)	% Change
Royalty Revenue	\$20.9	\$14.7	42%

1) Dollar amounts and percentages, as presented, are rounded.



# First Quarter 2018 Financial Highlights<sup>1</sup>

\$ U.S. in Millions, except EPS (unaudited)

	1Q 2018	1Q 2017	% Change
Total Revenue	\$30.9	\$29.6	4%
Total Operating Expense	\$54.6	\$57.1	(4%)
Cost of Product Sales	\$3.1	\$7.5	(60%)
R&D Expense	\$38.0	\$36.9	3%
SG&A Expense	\$13.6	\$12.6	7%
Net Income / (Loss)	(\$27.5)	(\$32.9)	--
EPS	(\$0.19)	(\$0.26)	--
Cash and marketable securities	\$433.7	\$179.0	--

1) Dollar amounts and percentages, as presented, are rounded.

# 2018 Financial Guidance

	2018	
<b>Net Revenue</b> <ul style="list-style-type: none"> <li>Royalty Growth</li> <li>Product Sales</li> </ul>	\$115M to \$125M  25% - 30%  API product orders lower as a result of planned partner manufacturing transition	<ul style="list-style-type: none"> <li>Does not include potential new ENHANZE<sup>®</sup> agreements</li> </ul>
<b>Operating Expenses</b>	\$230M to \$240M	<ul style="list-style-type: none"> <li>Disciplined expense control, flat to 2017</li> </ul>
<b>Operating Cash Burn</b>	(\$75M) to (\$85M)	<ul style="list-style-type: none"> <li>Excludes impact of financing, repayment of debt principal</li> </ul>
<b>Debt Repayment</b>	~(\$95M)	<ul style="list-style-type: none"> <li>Includes royalty-backed and Oxford/SVB loans</li> </ul>
<b>Year-end Cash</b>	\$305M to \$315M	<ul style="list-style-type: none"> <li>Cash runway into 2020</li> </ul>



First Quarter 2018

Earnings Call

May 10, 2018